JP2016525114A - C型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ - Google Patents
C型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ Download PDFInfo
- Publication number
- JP2016525114A JP2016525114A JP2016527033A JP2016527033A JP2016525114A JP 2016525114 A JP2016525114 A JP 2016525114A JP 2016527033 A JP2016527033 A JP 2016527033A JP 2016527033 A JP2016527033 A JP 2016527033A JP 2016525114 A JP2016525114 A JP 2016525114A
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- interferon
- compound
- compounds
- ns5a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361847388P | 2013-07-17 | 2013-07-17 | |
US61/847,388 | 2013-07-17 | ||
PCT/US2014/046685 WO2015026454A1 (en) | 2013-07-17 | 2014-07-15 | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis c virus |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016525114A true JP2016525114A (ja) | 2016-08-22 |
JP2016525114A5 JP2016525114A5 (zh) | 2017-07-27 |
Family
ID=51293156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016527033A Pending JP2016525114A (ja) | 2013-07-17 | 2014-07-15 | C型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3021846A1 (zh) |
JP (1) | JP2016525114A (zh) |
CN (1) | CN105555266B (zh) |
WO (1) | WO2015026454A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN108348504B (zh) * | 2015-11-06 | 2021-06-29 | 江苏豪森药业集团有限公司 | 具有抑制hcv活性的化合物及其制备方法和应用 |
CN108349907B (zh) * | 2015-11-06 | 2021-08-31 | 江苏豪森药业集团有限公司 | 1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010500413A (ja) * | 2006-08-11 | 2010-01-07 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎ウイルス阻害剤 |
WO2012009394A2 (en) * | 2010-07-16 | 2012-01-19 | Bristol-Myers Squibb Company | Methods to identify combinations of ns5a targeting compounds that act synergistically to inhibit hepatitis c virus replication |
WO2012166716A2 (en) * | 2011-05-27 | 2012-12-06 | Achillion Pharmaceuticals, Inc. | Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2438802A (en) | 2005-02-28 | 2007-12-05 | Univ Rockefeller | Structure of the hepatitis C virus NS5A protein |
SG178952A1 (en) * | 2009-09-04 | 2012-04-27 | Glaxosmithkline Llc | Chemical compounds |
US8415374B2 (en) * | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
US9326973B2 (en) * | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2014
- 2014-07-15 WO PCT/US2014/046685 patent/WO2015026454A1/en active Application Filing
- 2014-07-15 JP JP2016527033A patent/JP2016525114A/ja active Pending
- 2014-07-15 CN CN201480050770.5A patent/CN105555266B/zh not_active Expired - Fee Related
- 2014-07-15 EP EP14748036.2A patent/EP3021846A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010500413A (ja) * | 2006-08-11 | 2010-01-07 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎ウイルス阻害剤 |
WO2012009394A2 (en) * | 2010-07-16 | 2012-01-19 | Bristol-Myers Squibb Company | Methods to identify combinations of ns5a targeting compounds that act synergistically to inhibit hepatitis c virus replication |
WO2012166716A2 (en) * | 2011-05-27 | 2012-12-06 | Achillion Pharmaceuticals, Inc. | Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections |
Also Published As
Publication number | Publication date |
---|---|
CN105555266A (zh) | 2016-05-04 |
WO2015026454A1 (en) | 2015-02-26 |
CN105555266B (zh) | 2018-11-30 |
EP3021846A1 (en) | 2016-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023535701A (ja) | 抗ウイルス剤としての官能化ペプチド | |
JP5815746B2 (ja) | C型肝炎ウイルス阻害剤 | |
DK2784075T3 (en) | Hepatitis C viral inhibitors | |
JP5632910B2 (ja) | C型肝炎ウイルス阻害剤 | |
CN103827108B (zh) | 丙型肝炎病毒抑制剂 | |
KR20120133366A (ko) | C형 간염 바이러스 억제제 | |
KR20110134497A (ko) | C형 간염 바이러스 억제제 | |
KR20120034603A (ko) | C형 간염 바이러스 억제제 | |
TW200938191A (en) | Hepatitis C virus inhibitors | |
KR20110124774A (ko) | C형 간염 바이러스 억제제 | |
CN101648944A (zh) | 病毒聚合酶抑制剂 | |
KR20100123717A (ko) | C형 간염 바이러스 억제제로서의 헤테로시클릭 유도체 | |
PT2250163E (pt) | Inibidores do vírus da hepatite c | |
JP2011521965A (ja) | C型肝炎ウイルス阻害剤 | |
KR20140045903A (ko) | C형 간염 바이러스 억제제 | |
JP2023537402A (ja) | 抗ウイルス剤としての機能化ペプチド | |
JP2014534206A (ja) | C型肝炎ウイルス阻害剤 | |
CN111315734B (zh) | 作为食欲素受体拮抗剂的经取代的2-氮杂双环[3.1.1]庚烷和2-氮杂双环[3.2.1]辛烷衍生物 | |
CA2914529A1 (en) | Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | |
JP2016525114A (ja) | C型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ | |
JP2016527232A (ja) | Hcvの治療に使用するためのビフェニル誘導体を含む組み合わせ | |
US9717712B2 (en) | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus | |
NZ787942A (en) | Nitrile-containing antiviral compounds | |
WO2023107417A1 (en) | Heterocyclic antiviral agents | |
WO2017023631A1 (en) | Hepatitis c virus inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170615 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170615 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180426 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181002 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190514 |